180 related articles for article (PubMed ID: 23519880)
1. At the center of health care policy making: the use of health technology assessment at NICE.
Stevens AJ; Longson C
Med Decis Making; 2013 Apr; 33(3):320-4. PubMed ID: 23519880
[TBL] [Abstract][Full Text] [Related]
2. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
3. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
4. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
5. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
6. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
[TBL] [Abstract][Full Text] [Related]
7. Some inconsistencies in NICE's consideration of social values.
Paulden M; O'Mahony JF; Culyer AJ; McCabe C
Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
[TBL] [Abstract][Full Text] [Related]
8. Estimating 'costs' for cost-effectiveness analysis.
Miners A
Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
[TBL] [Abstract][Full Text] [Related]
9. The role of health economics in the evaluation of surgery and operative technologies.
Taylor M
Surgery; 2017 Feb; 161(2):300-304. PubMed ID: 28096035
[TBL] [Abstract][Full Text] [Related]
10. Can the NICE "end-of-life premium" be given a coherent ethical justification?
Cookson R
J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
[TBL] [Abstract][Full Text] [Related]
11. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
12. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
O'Mahony JF; Paulden M
Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
[TBL] [Abstract][Full Text] [Related]
13. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
Taylor R
Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
[TBL] [Abstract][Full Text] [Related]
14. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
15. An empirical ethics study of the coherence of NICE technology appraisal policy and its implications for moral justification.
Charlton V; DiStefano M
BMC Med Ethics; 2024 Mar; 25(1):28. PubMed ID: 38448909
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
17. Evidence and values: paying for end-of-life drugs in the British NHS.
Chalkidou K
Health Econ Policy Law; 2012 Oct; 7(4):393-409. PubMed ID: 23079299
[TBL] [Abstract][Full Text] [Related]
18. Exorcising the positivist ghost in the priority-setting machine: NICE and the demise of the 'social value judgement'.
Charlton V; Weale A
Health Econ Policy Law; 2021 Oct; 16(4):505-511. PubMed ID: 33568251
[TBL] [Abstract][Full Text] [Related]
19. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
Kaltenthaler E; Papaioannou D; Boland A; Dickson R
Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
[TBL] [Abstract][Full Text] [Related]
20. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
Charlton V
J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
